Download letters

CURRICULUM VITAE
MICHAEL JOSEPH BOYER
28 June 2017
1
CURRICULUM VITAE
28 June 2017
PERSONAL DATA
Name: Michael Joseph Boyer
Date of Birth: 27 Aug 1960
Place of Birth: Sydney, Australia.
Address: Royal Prince Alfred Hospital, Missenden Rd Camperdown, NSW 2050
EMPLOYMENT
2007 – present
Director of Suydney Cancer Centre, and Area Cancer Services, Sydney
South West Area Health Service. Clinical Associate Professor, Department
of Medicine, University of Sydney.Senior Staff Specialist, Department of
Medical Oncology, Sydney Cancer Centre (Royal Prince Alfred and
Concord Hospitals).
2005 -2007
Clinical Associate Professor, Department of Medicine, University of
Sydney.Senior Staff Specialist and Area Head, Department of Medical
Oncology, Sydney Cancer Centre (Royal Prince Alfred and Concord
Hospitals).Area Director of Medical Oncology, Sydney South West Area
Health Service
2001–2005:
Clinical Associate Professor, Department of Medicine, University of
Sydney.Senior Staff Specialist and Area Head, Department of Medical
Oncology, Sydney Cancer Centre (Royal Prince Alfred and Concord
Hospitals).
1995-2001:
Clinical Senior lecturer, Department of Medicine, University of Sydney.
Senior Staff Specialist and Area Head, Department of Medical Oncology,
Sydney Cancer Centre (Royal Prince Alfred and Concord
Hospitals).Visiting Medical Oncologist, Dubbo Base Hospital (until 1998)
1993-1995:
Staff Specialist in Medical Oncology, Royal Prince Alfred Hospital, Sydney.
Visiting Medical Oncologist, Dubbo Base Hospital
Research Fellow and Clinical Fellow, Ontario Cancer Institute and Princess
Margaret Hospital, Toronto, Canada. Recipient of Medica’ Research
Council of Canada Research Fellowship.
1990-1993:
1989:
Haematology Registrar, Royal Prince Alfred Hospital (6 months) and
Radiation Oncology Registrar, Westmead Hospital (6 months)
1988:
Medical Oncology Registrar, Royal Prince Alfred Hospital
2
1986-1987:
Medical Registrar, Royal Prince Alfred Hospital
1985:
Medical Resident, Royal Prince Alfred Hospital
1984:
Intern, Royal Prince Alfred Hospital, Sydney, Australia.
EDUCATION
PhD, 1993, University of Toronto
Fellow of The Royal Australasian College of Physicians, conferred December 1990.
Specialty training in Medical Oncology, 1988-90.
MB.BS. with First Class Honors, (Bachelor of Medicine , Bachelor of Surgery) 1984,
University of Sydney.
Prizes:
Prize for Physiology 1980
Prize for Biochemistry 1980
School (primary & secondary) Sydney Grammar School, 1966-1978
Awards:
School Prefect.
Seventh in State of NSW in Higher School Certificate Examination
COMMITTEES
Member Radiotherapy Information Strategy Steering Committee (NSW Health) 1998.
Member, National Health and Medical Research Council Working Party on Beam and
Isotope Radiotherapy, 1993.
Chairman COSA Lung Group 1994-6
Chairman, Program Committee, Clinical Oncological Society of Australia Annual
Scientific Meeting 1995
Member of Program Committee, Genito-Urinary Oncology Group Scientific Meeting July
1997
Chairman, Scientific Committee (Oncology) International Congress of Chemotherapy,
Sydney 1997
Member, Royal Prince Alfred Hospital Drug Committee, 1993 - 1999.
Sydney Cancer Centre Management Committee 1995 - present
Treasurer, Royal Australasian College of Physicians, 2000 – present
Member, International Scientific Committee, 10th World Conference on Lung Cancer,
Vancouver 2003.
3
Chairman, Scientific Advisory Committee, Australasian Lung Cancer Trials Group 2004 –
present.
MEMBERSHIP OF SOCIETIES
Member of the Clinical Oncological Society of Australia
Member of the American Society of Clinical Oncology
Member of the American Association for Cancer Research
Member of the Medical Oncology Group of Australia
Member of the International Association for the Study of Lung Cancer
Member of Australasian Lung Cancer Trials Group
PEER REVIEWED GRANTS
Boyer MJ, Butow PN, Dunn,SM. Why do cancer patients use alternative therapies. NSW
Dept of Health, Customer Focus Unit, 1995. $9,700.
Dunn SM, Butow PN, Boyer MJ. Improving communication in the cancer consultation:
optimal strategies and empirical outcomes. PHDRC, 19967. $147,627.
Cheung A, Boyer MJ. Tumour-specific generation of a cytotoxic agent by aminopeptidase
 antibody conjugates. Leo and Jenny Foundation. 1996. $50,000.
Khadra M, Boyer MJ, Bishop JF. The development of 3D image analysis for the
enhancement of prostate cancer diagnosis on transrectal ultrasound. Prostate Cancer
Research Foundation 1997-98. $41,530
Viney R, Fulham M, King M, Boyer MJ, McCaughan B. Economic evaluation of positron
emission tomography in management of non-small cell lung cancer. NHMRC 1999 - 2001.
$284,121
Clark S, Sutherland R, Henshall S, Russell P, Horvath L, Boyer M, Lee CS et al. Methods
to predict metastatic spread and responsiveness to chemotherapy in prostate cancer
patients with hormonal resistant disease. Cancer Institute NSW 2005 – 2010 $3,750,000
Olver I, Toner G, Marshall V, Boyer M, Mauruff P. The effects of chemotherapy on cognitive
function in patients with testicular cancer. NSW Cancer Council 2006 – 2008. $331,000
Davidson A, Boyer M, Fong K, Singhal N, McLachlan S, Stockler M. A randomised phase III
trial of adding nitroglycerin to first line chemotherapy in advanced non-small cell lung cancer.
NSW Cancer Council 2008 – 2009. $197,850
4
PUBLICATIONS
Peer Reviewed Papers
1. Boyer MJ, Friedlander ML, Bannatyne P and Atkinson KH. Hypercalcaemia in
association with mucinous adenocarcinoma of the ovary: a case report. Gynae Oncol,
1989; 35: 387-390.
2. Boyer MJ, Raghavan D, Harris PJ, et al. Lack of late toxicity in patients treated with
cisplatin-containing combination chemotherapy for testicular cancer. J Clin Oncol,
1990; 8: 21-26.
3. Boyer MJ, Tattersall MHN. Diethylstilbestrol revisited in advanced breast cancer
management. Medical and Pediatric Oncology, 1990; 18: 317-320.
4. Tannock IF, Boyer MJ, Karuri A, et al. Prospects for drugs exploiting lower tumor
pH. In Dewey WC, Edington M, Fry RJM, Hall EJ, Whitmore GF (eds), Radiation
Research: A twentieth century perspective. Academic Press, San Diego, 1992.
5. Celermajer DS, Boyer MJ, Bailey B, Tattersall MHN. Pericardiocentesis for
symptomatic malignant pericardial effusion: a study of 36 patients. Med J Aust, 1991;
154: 19-22.
6. Stuart-Harris R, Boyer MJ, Greenberg M, Stevens S, Yung T. The histopathological
classification of small cell lung cancer: application of the IASLC classification in124
cases. Lung Cancer, 1992; 8: 63-70.
7. Boyer MJ, Tannock IF. Regulation of intracellular pH in tumor cell lines; influence of
microenvironmental conditions. Cancer Research, 1992; 52: 4441-4447.
8. Boyer MJ, Tannock IF. Lysosomes, lysosomal enzymes and cancer. Advances in
Cancer Research, 1993; 60: 269-291.
9. Boyer MJ, Horn I, Steele-Norwood D, Firestone R, Tannock IF. pH dependent cell
killing by acid activated detergents. British Journal of Cancer, 1993; 67: 81-87.
10.Deslile L, Boyer MJ, Warr D, et al. Ectopic adrenocorticotrophic syndrome and small
cell carcinoma of the lung: assessment of clinical features, outcome and complications
of chemotherapy. The Archives of Internal Medicine, 1993; 153: 746-752.
11.Boyer MJ, Barnard M, Hedley DW, Tannock IF. Regulation of intracellular pH in
subpopulations of cells derived from spheroids and solid tumors. British Journal of
Cancer, 1993 ; 68: 890-897
12.Clarke SJ, Boyer MJ. Recent advances in managing non-small-cell lung cancer:
Chemotherapy of metastatic cancer. Med J Aust, 1997; 166 (Suppl): S14-S16.
5
13.Ellis P, Stockler M, Boyer MJ. The occurrence of germ cell malignancies in two
patients positive for HIV. International Journal of STD and AIDS, 1997;8: 526-7
14.Herman SM, Robinson JTC, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS.
Androgen deprivation is associated with enhanced endothelium-dependent dilatation in
adult men. Arteriosclerosis, Thrombosis and Vascular Biology, 1997; 17: 2004-2009
15.Boyer MJ, Cox K, Tattersall MHN, Findlay MPN, Grygiel JJ, Rogers J. Active
surveillance after orchidectomy for non-seminomatous germ cell tumours: late relapse
may occur. Urology, 1997; 50: 588-92
16.Boyer MJ, Zalcberg J, Olver IN, Millward MJ, Richardson G, McKeage MJ. Phase I
study of paclitaxel and oral etoposide in previously untreated non-small cell and
extensive small cell lung cancer. Ann Oncol, 1997; 8: 485 - 489
17.Butow PN, Maclean M, Dunn SM, Tattersall MHN, Boyer MJ. The dynamics of
change. Cancer patients’ preferences for information involvement and support. Ann
Oncol, 1997; 8: 857-863
18.Boyer MJ. Bioreductive agents: a clinical update. Oncology Research, 1997; 9: 391395
19.Miller M, Boyer MJ, Butow PN, Gatellari M, Childs A, Dunn S. The use of unproven
methods of treatment by cancer patients: frequency, expectations and cost. Supp Care
Cancer, 1998; 6: 337 - 347
20.Brown R, Butow PN, Boyer MJ, Tattersall MHN. Promoting patient participation in
the cancer consultation: evaluation of a prompt sheet and coaching in question asking.
Br J Cancer, 1999; 80: 242 - 248
21.Yip D, Findlay M, Boyer M, Tattersall MH. Hepatocellular carcinoma in central
Sydney: a 10-year review of patients seen in a medical oncology department. World
Journal of Gastroenterology, 1999; 5: 483 – 487
22.von Pawel J, von Roemeling R, Gatzemeier U, Boyer M, Elisson LO, Clark P, et al.
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung
Cancer: A Report of the International CATAPULT I Study Group. J Clin Oncol, 2000;
18: 1351-1359.
23.Dowsett SM, Saul JL, Butow PN, Dunn SM, Boyer MJ, Findlow R, Dunsmore J.
Communication styles in the cancer consultation: preferences for a patient-centred
approach. Psycho-oncology, 2000; 9: 147 – 156.
24.Rischin D, Boyer M, Smith J, et al. A phase I trial of docetaxel and gemcitabine in
patients with advanced cancer. Ann Oncol, 2000; 11: 421-426.
25.Klastersky J, Paesmans M, Rubenstein E, Boyer M, Elting L, Feld R, et al. The
MASCC risk index: a multinational scoring system to predict low-risk febrile
neutropennic cancer patients. J Clin Oncol, 2000; 18: 3038 – 3051.
6
26.Rischin D, Smith J, Millward M, Lewis C, Boyer M, Richardson G, Toner G, Gurney
H, McKendrick J. A phase II trial of paclitaxel and epirubicin in advanced breast
cancer. Br J Cancer, 2000; 83: 438 – 442.
27.Rivory LP, Slaviero K, Seale JP, Hoskins JM, Boyer M, Beale PJ, Millward MJ,
Bishop JF, Clarke SJ. Optimising the erythromycin breath test for use in cancer
patients. Clinical Cancer Research, 2000; 6: 3480 - 3485.
28.Horvath LG, McDowell D, Stevens G, Parkinson R, McCarthy S, Boyer MJ. Unusual
presentations of germ cell tumors. J Clin Oncol, 2001; 19: 909-916
29.Boyer MJ, Mitchell P, Goldstein D, Millward MJ, Olver IN, Clarke SJ, Richardson G,
Davis I. Phase II study of paclitaxel and oral etoposide in patients with locally advanced
or metastatic non-small cell lung cancer. Lung Cancer, 2001; 32: 89 - 94.
30.Toner G, Stockler MR, Boyer MJ, Jones M, Thompson DB, Harvey VJ, et al
Comparison of two standard chemotherapy regimens for good-prognosis germ cell
tumours: a randomised trial. Lancet, 2001; 357: 739 – 745.
31.Boyer MJ, Stockler MR. Testicular cancer management; we have to keep our eye on
the ball. Med J Aust, 2001; 174: 320 – 321.
32.Horvath LG, Boyer MJ, Clarke SJ, Beale P, Beith J, Underhill C, Stockler M, Bishop
J. Carboplatin and Vinorelbine in untreated locally advanced and metastatic non-small
cell lung cancer. Lung Cancer, 2001; 32: 173 – 178.
33.Twelves C, Boyer M, Findlay M, Cassidy J, Weitzel C, Barker C, et al. Capecitabine
improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase
III trial conducted in patients with advanced colorectal carcinoma. Eur J Cancer, 2001;
37: 597 – 604.
34.Boyer MJ. Diagnosis and management of testicular cancer. Current Therapeutics,
2001; 42: 25 – 29.
35.Van Cutsem E, Twelves C, Cassidy J, Allman D, Bajetta E, Boyer M, et al. Oral
capecitabine compared with intravenous fluorouracil plus leucovorin in patients with
metastatic colorectal cancer: results of a large phase III study. J Clin Oncol, 2001; 19:
4097 – 4106.
36.Rivory LP, Clarke SJ, Boyer M, Bishop JF. Highly sensitive analysis of the antifolate
pemetrexed sodium, a new cancer agent, in human plasma and urine by highprtformance liquid chromatography. Journal of Chromatography B, 2001; 765: 135 –
140.
37.Horvath LG, McCaughan BC, Stockler M, Boyer MJ. Resection of residual pulmonary
masses after chemotherapy in patients with metastatic non-seminomatous germ cell
tumours. Internal Medicine Journal, 2002; 32: 79 – 83.
38.Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial
of pemetrexed disodium (ALIMTA, LY231514) in chemotherapay mnaive patients with
7
advanced non-small-cell lung cancer (NSCLC). Ann Oncol, 2002; 13: 737 - 741.
39.Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral
capecitabine therapy in metastatic colorectal cancer: a favourable safety profile
compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol, 2002; 13: 566 – 575.
40.Boyer MJ, Rosenthal MA, Eisinger D, Goad J, Webb D, Stockler MR. Adjuvant
mitoxantrone chemotherapy for men at high risk of relapse following radical
prostatectomy: a pilot study. UroOncology, 2002; 2: 15 – 17.
41.Millward MJ, Boyer MJ, Lehnert M, et al. Docetaxel and carboplatin is an active
regimen in advanced non-small cell lung cancer: a phase II study in Caucasian and
Asian patients. Ann Oncol, 2003; 14: 449 – 454.
42.Advanced Bladder Cancer Meta-Analysis Collaboration. Neoadjuvant chemotherapy in
invasive bladder cancer: a systematic review and meta-analysis. Lancet, 2003; 361:
1927 – 1934. (member of collaboration, and involved in drafting final paper).
43.Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P,
Gatzemeier U, Boyer M, et al. Phase III study of pemetrexed in combination with
cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin
Oncol, 2003; 21: 2636 – 2644.
44.Zhang M, Boyer M, Rivory L, et al. Radiosensitization of vinorelbine and gemcitabine
in NCI-H460 non-small cell lung cancer cells. Int J Radiation Oncology Biol Phys,
2004; 58: 353 – 360.
45.Viney R, Boyer MJ, King MT, et al. A randomised controlled trial of the role of
positron emission tomography in the management of Stage I and II non-small cell lung
cancer. J Clin Oncol 2004; 22: 2357 – 2362.
46.Butow P, Devine R, Boyer M, et al. A cancer consultation preparation package:
Changing patients but not doctors is not enough. J Clin Oncol 2004; 22: 4401 – 4409.
47.Vardy J, Engelhardt K, Jacquet J, McDade A, Boyer M, Beale P, et al. Long-term
outcome of radiological-guided insertion of implanted central venous access port
devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional
experience and review of the literature. Br J Cancer 2004; 91: 1045 – 1049.
48.Sharma R, Boyer M, Clarke S, Millward M. Gefitinib in advanced non-small cell lung
cancer. Internal Medicine Journal 2005; 35: 77 – 82.
49.Joshua A.M., Boyer M.J., Subramanian R. and Clarke S.J. Smoking reduction does
work: Resulting alterations in the incidence and histological subtypes of lung cancer in
New south wales in the last 20 years. Respirology 10;233-238, 2005
50.Boyer M. The importance of balancing toxicity and efficacy in chemotherapy: focus on
pemetrexed. Am J Cancer 2005; 4: 127 – 136.
51.Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ. Weekly
docetaxel as second line treatment after mitozantrone for androgen-independent
8
prostate cancer. Internal Medicine Journal 2005; 35: 468 – 472.
52.Clarke SJ, Boyer MJ, Millward M, Underhill C, Moylan E, Yip D, et al. A phase I/II
study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung
Cancer 49(3):401-12, 2005
53. Stockler MR, Tattersall MHN., Boyer MJ., Clarke SJ., Beale P. and Simes RJ.
Disarming the gurded prognosis: predicting survival in newly referred patients with
incurable cancer. British Journal of Cancer 2006; 94: 208 – 212.
54. Abratt RP, Lee JS, Han JY, Tsai C-M, Boyer M, Mok T, et al. Phase II trial of
gemcitabine-carboplatin-paclitaxel as neoadjuvant chemotherapy for operable nonsmall cell lung cancer. Journal of Thoracic Oncology 2006; 1: 135 – 140.
55. Soo RA, Wang LZ, Tham LS, Yong WP, Boyer M, Lim HL, et al. A multicentre
randomised phase II study of carboplatin in combination with gemcitabine at standard rate
or fixed dose rate infusion in patients with advanced stage non-small cell lung cancer. Ann
Oncol. 2006; 17: 1128 – 33.
56. Cebon J, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer M, et al.
Somatostatin receptor expression, tumour response and quality of life in patients with
advanced hepatocellular carcinoma treated with long-acting octreotide.Br J Cancer. 2007;
96: 1154
57. Findlay M, Storey D, Gebski V, Hargreaves C, Cullingford G, Boyer M, et al. A pilot
study of preoperative and postoperative chemotherapy in patients with operable gastric
cancer: Australasian Gastrointestinal Trials Group Study 9601. ANZ J Surg. 2007; 77: 247
– 52.
58. Yeo W, Boyer M, Chung HC, Ong SY, Lim R, Zee B, et al. Irofulven as first line therapy
in recurrent or metastatic gastric cancer: a phase II multicentre study by the Cancer
Therapeutics Research Group. Cancer Chemother Pharmacol. 2007; 59: 295 – 300.
59. Oates JE, Clark JR, Read J, Reeves N, Gao K, Jackson M, Boyer M, O’Brien CJ.
Prospective evaluation of quality of life and nutrition before and after treatment for
nasopharyngeal cancer. Arch Otolaryngol Head Neck Surg 2007; 133: 533 – 540.
60. Chuah B, Lim R, Boyer M, Ong AB, Wong AW, Kong HL, et al. Multi-centre phase II
trial of thalidomide in the treatment of unresectable hepatocellular carcinoma. Acta
Oncologica. 2007; 46: 234 – 38.
61. Kenny PM, King MT, Viney RC, Boyer MJ, Pollicino CA, McLean JM, et al. Quality of
life and survival in the 2 years after surgery for non-small cell lung cancer. J Clin Oncol
2008; 26: 233 – 241.
62. Vinod SK, O’Connell DL, Simonella L, Delaney GP, Boyer M, Peters M, et al. Gaps in
optimal care for lung cancer. J Thoracic Oncol 2008; 3: 871 – 879.
63. Martin RC, Fulham M, Shannon K, Hughes C, Gao K, Milross M, Tin MM, Jackson M,
Clifford A, Boyer MJ, O’Brien CJ. Accuracy of positron emission tomography in the
9
evaluation of patients treated with chemoradiotherapy for mucosal head and neck cancer.
Head and Neck 2009; 31: 244 – 250.
64. Vardy J, Dadasovich R, Beale P, Boyer MJ, Clarke SJ. Eligibility of patients with
advanced non-small cell lung cancer for phase III chemotherapy trials. BMC Cancer 2009;
9: 130.
65. Simonella L, O’Connell DL, Vinod SK, Delaney GP, Boyer M, Esmaili N, et al. No
improvement in lung cancer care: the management of lung cancer in 1996 and 2002 in New
South Wales. Intern Med J 2009 (in press)
66. Soon YY, Stockler MR, Askie L, Boyer MJ. Duration of chemotherapy for advanced nonsmall cell lung cancer: a systematic review and meta-analysis of randomized trials. J Clin
Oncol 2009 (in press).
67. Pezaro C, Rosenthal MA, Gurney H, Davis ID, Underhill C, Boyer MJ, et al. An openlabel single arm phase two trial of gefitinib in patients with advanced or metastatic
castration-resistant prostate cancer. Am J Clin Oncol 2009 (in press)
Invited Papers
1. Tattersall MHN, Boyer MJ. The management of malignant pleural effusions. Thorax,
1990; 45: 81-82.
2. Raghavan D, Boyer MJ. Active surveillance for stage I non-seminomatous germ cell
testis tumors: practice and pitfalls. Prog Clin Biol Res, 1990; 350: 309-318.
3. Tannock IF, Boyer MJ. When is a cancer treatment worthwhile? N Engl J Med, 1990;
323: 989-990.
4. Boyer MJ, Tannock IF. Commentary on "Drug resistance testing". Oncology, 1991; 5:
104.
5. Boyer MJ and Raghavan D. Toxicity of treatment of germ cell tumors. Sem. Oncol.,
1992; 19: 128-142.
6. Boyer MJ, McGeer A, Feld,R. Recent advances in the management of infections in
cancer patients. Crit Rev Oncol Hematol, 1993; 15: 175-190
7. Boyer MJ, Raghavan D. Long Term Morbidity of Treatment of Testicular Cancer.
Problems in Urology, 1994; 8:154-166.
8. Boyer MJ, Hedley DW. Measurement of Intracellular pH. Methods In Cell Biology,
1994; 41: 135-148.
9. Boyer MJ. Management of prostate cancer. Australian Prescriber, 1996; 19: 22-24
10
10.Boyer MJ. The economics of lung cancer. Lung Cancer, 1996; 14: 13-17
11.Boyer MJ. Medical management of primary hepatocellular carcinoma. Australian
Chinese Medical Association Journal, 1997; 2: 57-58.
12.Boyer MJ. New chemotherapeutic agents in the treatment of non-small cell lung
cancer: the Australian experience. Chest, 1998; 113: S24 - S27.
13.Clarke S, Boyer M. Non-surgical therapy for patients with advanced non-small cell
lung cancer. Respirology, 1998; 3: 175 - 182.
14.Boyer MJ. Testicular cancer: diagnosis and management. New Ethicals Journal, 2002;
5: 29 – 34
15.Boyer MJ, Clarke SJ. Current Management of Lung Cancer. Current Therapeutics,
2002; 43: 49 – 54.
16.Boyer MJ, Rivory LP, Clarke SJ. Pemetrexed: single agent and combination phase I
study overview. Semin Oncol, 2002; 29, Suppl 18: 18 – 23.
17.Boyer M, Byrne M, Clarke S. Alimta: a new treatment option for malignant
mesothelioma. Reviews in Clinical Oncology, 2003; 1: 4 – 8.
18.Boyer MJ. Drug therapy of lung cancer. Aust Prescr, 2003; 26: 103 – 105.
19.van Meerbeeck JP, Boyer M. Consensus report: pre-treatment minimal staging and
treatment of potentially resectable malignant pleural mesothelioma. Lung Cancer 2005;
49S1: S123 – S127.
Book Chapters
1. Raghavan D, Boyer MJ. Extragonadal germ cell tumours. In
Testicular Cancer.,pages 297-317. Chapman and Hall, 1991.
Horwich A (ed),
2. Boyer MJ, Raghavan D. Extragonadal germ cell tumours. In The Oxford Textbook of
Oncology, 1995; 1439-1449.
3. Boyer MJ, Roth B. Side effects of treatment for testicular cancer. In Raghavan D,
Scher HI, Liebel S, Lange P eds, Principles and Practice of Genitourinary Oncology,
1997; 741-749.
4. Raghavan D, Boyer MJ. Extragonadal germ cell tumours. In Horwich A(ed),
Testicular Cancer. 2nd edition Chapman and Hall, 1996; 345-368.
5. Boyer MJ. Medical Oncology. In Kearsley JH, Morris DL, Williams CJ (eds), Cancer
A Comprehensive Clinical Guide, pages 47 - 56. 1998 Harwood Academic Publishers,
Amsterdam.
11
6. Boyer MJ, Tannock IF. Cellular and molecular basis of chemotherapy. In Tannock IF,
Hill R (eds), The Basic Science of Oncology. 2nd Edition, 1998. McGraw Hill, New
York.
7. Boyer M, Jackson M. Cancers of the Urogenital Tract: Systemic and Radiation
Treatment. In Bishop JF (ed) Cancer Facts: a concise oncology text, pages 209 - 213.
1999 Harwood Academic Publishers, Amsterdam.
8. Boyer M. Non-Small Cell Lung Cancer: Chemotherapy. In Bishop JF (ed) Cancer
Facts: a concise oncology text, pages 118 - 120. 1999 Harwood Academic Publishers,
Amsterdam.
9. Boyer MJ, MacLeod C. Small cell carcinoma of the lung. In Harnett P, Cartmill J,
Glare P (eds) Oncology: A case based manual, pages 78 – 81, 1999. Oxford University
Press, Oxford.
10.Boyer MJ, MacLeod C. Non-small cell lung cancer. In Harnett P, Cartmill J, Glare P
(eds) Oncology: A case based manual, pages 81 – 85, 1999. Oxford University Press,
Oxford.
11.Boyer MJ and Raghavan D. Extragonadal germ cell tumours. In Souhami RL,
Tannock, I, Hohenberger P, Horiot J-C (eds) Oxford Textbook of Oncology 2nd edition,
pages 2037 – 2045. Oxford University Press, Oxford 2002.
12.Boyer MJ. Pleural and pericardial effusions. In Fisch MJ & Bruera E (eds) Handbook
of Advanced Cancer Care, pages 481 – 487. Cambridge University Press, Cambridge
2003.
13.Horvath L, Boyer MJ. Acute Toxicity of Chemotherapy. In Raghavan D (ed) Germ
Cell Tumors, pages 340 – 348. BC Decker Inc, Hamilton 2003
LETTERS
1. Viney RC, Fulham MJ, McCaughan BC, Boyer MJ, Hall JP. Evaluation of the role of
positron emission tomography in oncology. Med J Aust, 2000; 172: 459 – 460.
ABSTRACTS
1. Boyer MJ and Tattersall MHN. Diethylstilbestrol in advanced breast cancer.
Proceedings of the Clinical Oncological Society of Australia 1988.
2. Boyer MJ and Raghavan D. Intensive late toxicity assessment program (LTAP) for
patients treated for metastatic germ cell tumours with cisplatin-containing combination
chemotherapy. Proc. Amer. Soc. Clin. Oncol., 1989.
3. Boyer MJ, Raghavan D, et al. Pre-emptive intravenous CMV for high grade stage T2
- T4 TCC of bladder. Proceedings of the Clinical Oncological Society of Australia
1989.
12
4. Boyer MJ, Firestone R, Tannock IF. Release of lysosomal enzymes into cytoplasm as
a potential mechanism for pH dependent cell killing in tumors. Proc Amer Assoc.
Cancer. Res, 1991.
5. Boyer MJ, Tannock IF. Intracellular pH regulation in hypoxic MGH U1 bladder
carcinoma cells. Proceedings of the 4th International Meeting on Hypoxia Research,
1991.
6. Boyer MJ, Feld R, Warr D, et al. LDH alone does not predict relapse of small cell
lung cancer (SCLC). Proc Amer Assoc. Cancer. Res, 1992.
7. Boyer MJ, Cox K, McNeil E. Active surveillance for non-seminomatous germ cell
tumours: late relapse may occur. Proc COSA, 1994, 127.
8. Boyer MJ, Doubrovsky A, Coates AS. Melphalan enhances the cytotoxicity of
tirapazamine under hypoxic but not aerobic conditions. Proc Amer Assoc. Cancer. Res.,
1995.
9. Miller MJ, Boyer MJ, Dunn SM, Butow PN, Griffin AM. Why do Australian cancer
patients use unproven therapies? Proc COSA, 1995, 63.
10. Visvanathan K, McNeil E, Boyer MJ. Changing pattern of admissions in small cell
lung cancer patients treated at Royal Prince Alfred Hospital 1985 - 1992. Proc COSA,
1995, 117.
11. Findlay M, M Fulham, D Lord, D Storey, J Thompson, M Boyer, S Clarke, J Bishop.
Assessment Of Tumour Response With [18F]Fluorodeoxyglucose Positron Emission
Tomography (FDG-PET) In Phase I/II Drug Studies. Proceedings of the New Zealand
Society for Oncology Scientific Meeting, 1996, 23
12. Boyer M, Olver I, Millward M, Zalcberg J, Richardson G, McKeage M, Joughin J.
Phase I study of two schedules of taxol and oral etoposide in patients with small cell or
non-small cell lung cancer. Proc ASCO, 1996; 15: 1177
13. Herman SM, Robinson JTC, McCredie RJ, Adams MR, Boyer MJ, Celermajer DS.
Androgen deprivation is associated with enhanced endothelium-dependent dilatation in
adult men. ANZ J Med, 1997; 27: 91
14. Boyer M, Olver I, Millward M, Zalcberg J, Richardson G, McKeage M, Joughin J.
Phase I/II trial of paclitaxel and oral etoposide in patients with small cell or non-small
cell lung cancer. Lung Cancer, 1997; 18: 169
15. Clarke S, Boyer M, Millward M, Findlay M, Ackland S, Childs A, Brew S, Walcher
V, Watt D, Thornton D. Phase II study of LY231514 in patients with advanced nonsmall cell lung cancer. Lung Cancer, 1997; 18: 34
16. Clarke S, Boyer M, Millward M, Findlay M, Ackland S, Childs A, Brew S, Walcher
V, Watt D, Campbell L. Multi-targeted antifolate MTA (LY231514): an active agent in
advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol, 1998; 17: 1793
13
17. Boyer MJ, Zalcberg J, Clarke SJ, Millward MJ, Olver IN, Mitchell P, Richardson G,
Goldstein D. Phase II trial of taxol and oral etoposide in patients with advanced nonsmall cell lung cancer. Proc Amer Soc Clin Oncol, 1998; 17: 1840
18. Findlay M, Clarke SJ, Boyer MJ, Sullivan A, Dugan M, Statkevich P, Reyderman L,
Teriana N, Cox K. Temodal (temozolamide) in patients with hepatocellular carcinoma,
cirrhosis and portal hypertension: a phase II / pharmacokinetic study. Proc Amer Soc
Clin Oncol, 1998; 17: 923
19. Millward MJ, Bishop J, Lehnert M, Boyer M, et al. Phase II trial of docetaxel and
carboplatin in advanced non-small cell lung cancer. Proc Amer Soc Clin Oncol, 1999;
18: 1994
20. Boyer MJ, Rischin D, Millward MJ, et al. Phase I study of gemcitabine and docetaxel
in patients with advanced cancer. Proc Amer Soc Clin Oncol, 1999; 18: 785
21. Boyer MJ, Rosenthal MA, Eisinger D, et al. Pilot study of adjuvant mitoxantrone in
patients at high risk of relapse following radical prostatectomy for prostate cancer. Proc
Amer Soc Clin Oncol, 2000; 19: 1439
22. Gurney H, Boyer MJ, Millward MJ et al. Phase II study of mitoxantrone, carboplatin
and prednisolone in patients with hormone refractory prostate cancer. Proc Amer Soc
Clin Oncol, 2000; 19: 1455
23. Stockler M, Boyer MJ, Millward M, etr al. Ratings and importance of specific aspects
of health related quality of life in advanced hormone resistant prostate cancer. Proc
Amer Soc Clin Oncol, 2000; 19: 1467
24. Viney R, Fulham MJ, McCaughan BC, Boyer MJ, et al. Whole body FDG-PET in
apparently resectable NSCLC: outline and design of the first randomised controlled trial
of FDG-PET in NSCLC. Lung Cancer, 2000; 29 (Suppl 1): 868
25. Boyer MJ, Viney R, Fulham M, et al. A randomised trial of conventional staging (CS)
with or without positron emission tomography (PET) in patients (pts) with stage 1 or 2
non-small cell lung cancer (NSCLC). Proc Amer Soc Clin Oncol, 2001; 20; 1233
26. Millward M, Clarke S, Beale P, Boyer M, et al. Phase I trial of pemetrexed (Alimtatm)
and vinorelbine in patients (pts) with advanced cancer. Proc Amer Soc Clin Oncol,
2001; 20; 2102
27. Findlay MP, Ackland S, Gebski V, Yuen J, Boyer MJ, et al. Phase II study of
irinotecan, leucovorin and 5FU (ILF) in advanced gastric cancer. Proc Amer Soc Clin
Oncol, 2001; 20; 655
28. Kong HL, Boyer MJ, Lim R, Clarke S, Millward MJ, Wong JEL. Phase II trial of
thalidomide in unresectable hepatocellular carcinoma (HCC)—a cancer therapeutics
research group (CTRG) study. Proc Amer Soc Clin Oncol, 2001; 20; 2282
29. Rivory LP, Slaviero KA, Seale P, Dunleavey R, Gurney H, Boyer M, et al. Prognostic
inflammatory and nutritional index (PINI) correlates with hepatic drug metabolism in
14
cancer patients. Proc Amer Soc Clin Oncol, 2001; 20; 444
30. Vogelzang NJ, Rusthoven J, Paoletti P, Denham C, Kaukel E, Ruffie P, Gatzmeier U,
Boyer MJ, et al. Phase III single blinded study of pemetrexed + cisplatin vs. cisplatin
alone in chemonaive patients with malignant pleural mesothelioma. Proc Amer Soc
Clin Oncol, 2002; 21; 5
31. Slaviero K, Rivory LP, McLachlan A, Beale PJ, Sullivan A, Boyer MJ et al.
Pharmacokinetic-pharmacodynamic relationships of weekly docetaxel therapy. Proc
Amer Soc Clin Oncol, 2002; 21: 354.
32. Boyer MJ, Moore M, Leichman L, et al. Phase II study of the novel taxane BMS
184476 in previously treated patients with advanced adenocarcinoma involving the
stomach or gastroesophageal junction. Proc Amer Soc Clin Oncol, 2002; 21: 591.
33. Cullingford G, Findlay M, Storey D, Boyer MJ, et al. A phase II feasibility study of
pre-operative and post-operative chemotherapy in patients with advanced but operable
gastric cancer: an Australasian Gastro-Intestinal Trials Group study. Proc Amer Soc
Clin Oncol, 2002; 21: 695.
34. Stockler MR, Toner GC, Lewis C, Craft PS, Boyer MJ, et al. Health related quality of
life in a randomised trial of two standard chemotherapy regimens for good prognosis
germ cell tumours: the ANZ germ cell trials group good prognosis trial. Proc Amer Soc
Clin Oncol, 2002; 21: 743.
35. Featherstone CJ, Beale PJ, Fife K, Shakespeare T, Bishop JF, Stockler MR, Jackson
M, Boyer MJ. Phase I study of gemcitabine, vinorelbine, and radiotherapy in stage 3B
or mediaclly inoperable stage 1 – 3A non-small cell lung cancer. Proc Amer Soc Clin
Oncol, 2002; 21: 1339.
36. Boyer MJ, Clarke S, Millward MJ, et al. Phase I trial of pemetrexed and vinorelbine
in patients with advanced or metastatic cancer. Ann Oncol, 2002; 13 Supp 5: 24
37. Joshua AM, Ong S, Noney L,Millward M, Beale P, Clarke SJ, Beith J, Kelly G, Boyer
MJ. Phase 1 dose-escalation study of phenoxodiol in patients with advanced cancer.
Proc Amer Soc Clin Oncol, 2003; 22: 902.
38. Millward M, Parnis F, Byrne M, Powell A, Dunleavey R, Lynch K, Boyer MJ. Phase
II trial of imatinib mesylate in patients with advanced pleural mesothelioma. Proc Amer
Soc Clin Oncol, 2003; 22: 912.
39. Leung TW, Mo F, Leow CK, Kpng HL, Boyer MJ, et al. Multicenter validation of the
Chinese University Prognostic Index for hepatocellular carcinoma. Proc Amer Soc Clin
Oncol, 2003; 22: 1040.
40. Cebon JS, Findlay M, Hargreaves C, Stockler M, Thompson P, Boyer MJ, et al.
Somatostatin receptor expression and clinical effects of octreotide LAR in patients with
advanced hepatocellular carcinoma. Proc Amer Soc Clin Oncol, 2003; 22: 1163.
41. Boyer MJ, Gurney H, Rosenthal MA, et al. Randomised phase II study of gemcitabine
15
with either carboplatin or docetaxel in patients with locally advanced or metastatic
transitional cell carcinoma of the urothelium. Proc Amer Soc Clin Oncol, 2003; 22:
1568.
42. Rosenthal MA, Toner GC, Gurney H, Davis ID, Underhill C, Boyer MJ, et al.
Inhibition of the epidermal growth factor receptor in hormone refractory prostate
cancer: initial results of a phase II study of gefitinib. Proc Amer Soc Clin Oncol, 2003;
22: 1671.
43. Butow PN, Devine R, Tattersall MHN, Boyer MJ, et al. Preparing patients for
oncology consultations: a randomised controlled trial of patient activation materials.
Proc Amer Soc Clin Oncol, 2003; 22: 2109.
44. Gralla RJ, Hollen PJ, Liepa AM, Symanowski JT, Boyer MJ, et al. Improving quality
of life in patients with malignant pleural mesothelioma: results of the randomised
pemetrexed + cisplatin vs. cisplatin trial using the LCSS-meso. Proc Amer Soc Clin
Oncol, 2003; 22: 2496.
45. Vogelzang NJ, Emri S, Boyer MJ, et al. Effect of folic acid and vitamin B12
supplementation on risk benefit ratio from phase III study of pemetrexed + cisplatin
versus cisplatin in malignant pleural mesothelioma. Proc Amer Soc Clin Oncol, 2003;
22: 2644.
46. Vardy JL, Boyer MJ, Beale P, Barnes D, Clarke SJ. Patients in advanced non-small
cell lung cancer chemotherapy trials are not representative of the general lung cancer
population. Proc Amer Soc Clin Oncol, 2003; 22: 2668.
47. Beale PJ, Stockler MR, Tattersall MHN, Boyer MJ, Clarke SJ. Improving predictions
and discussion of survival time in people with incurable cancer: making the prognosis
less guarded. Proc Amer Soc Clin Oncol, 2003; 22: 3035.
48. Boyer MJ, Jassem J, Liepa AM, et al. Symptom and quality of life advantages for
pemetrexed + cisplatin versus cisplatin in treatment of malignant pleural mesothelioma.
Lung Cancer, 2003; 41: S19.
49. Boyer MJ. PET scanning for operable non-small cell lung cancer. Lung Cancer, 2003;
41: S15
INVITED PRESENTATIONS
The Tumour Microenvironment; Biology and Therapeutic Potential. Oncology Grand
Rounds, Prince of Wales Hospital, 18th February 1994.
Advances in Prostate Cancer. NSW Palliative Care Symposium, Sydney, 11th March
1994.
Can we believe what we read? A critical perspective of clinical trials in oncology. New
Zealand Society for Oncology Jubilee Conference, February 13th - 16th 1996 (delivered for
Ian Tannock).
16
Acidity in tumours: pH regulation and the potential for therapeutic exploitation. New
Zealand Society for Oncology Jubilee Conference, February 13th - 16th 1996 (delivered for
Ian Tannock).
New chemotherapeutic agents in the treatment of non-small cell lung cancer: Australian
experience. International Symposium on Thoracic Malignancies, Pittsburgh, April 25th 26th 1996.
New drugs for the treatment of lung cancer. University of Sydney Oncology Symposium,
Terrigal, August 10th - 11th 1996.
Tirapazamine, a novel hypoxic cytotoxin: preclinical rationale and clinical results in
combination with radiation therapy or chemotherapy. 3rd International Conference of the
Asian Clinical Oncology Society, Kunming, August 15th - 17th 1996.
Bioreductive agents: a clinical update. 2nd International Conference on Redox Processes
and Cancer, Banff, April 7th - 10th 1997.
Prostate and Testicular Cancer. Mens Health Update, Liverpool Hospital April 29th 1997.
Small Cell Lung Cancer. Asta Medica Lung Cancer Symposium, Sydney, June 4th 1997.
Chemotherapy for metastatic prostate cancer. Inaugural National Meeting of the
Genitourinary Oncology Group, Leura, July 25th - 27th.
The Management of Stage III Non-Small Cell Lung Cancer. Medical Oncology Group of
Australia Annual Meeting, Hamilton Island, September 5th - 7th 1997.
Recent Advances in the Management of Non Small Cell Lung Cancer. Satellite
Symposium, 4th National Cancer Conference, Bangkok, Thailand, November 11 1997.
The Management of Stage IIIA Non-Small Cell Lung Cancer. Royal Australasian College
of Surgeons Annual Scientific Meeting, Sydney May 1998
Neoadjuvant and Adjuvant hormonal therapy for prostate cancer. Medical Oncology
Group of Australia Annual Meeting, Queenstown, August 12th –16th 1998.
Induction Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer. Clinical
Oncological Society of Australia Annual Scientific Meeting, Sydney, November 25th – 27th
1998.
Update on the management of testicular cancer. Royal Prince Alfred Hospital Grand
Rounds. July 1999.
Testicular Cancer. Society of Neuromuscular Sciences Annual meeting, Thredbo, August
12th – 13th 1999.
Lung Cancer. Society of Neuromuscular Sciences Annual meeting, Thredbo, August 12th –
17
13th 1999.
Cancer Biology and The Promise of New Cancer Treatments. Society of Neuromuscular
Sciences Annual meeting, Thredbo, August 12th – 13th 1999.
New Drugs in the Treatment of Cancer. Chinese Society of Clinical Oncology 3rd Annual
Meeting, Dalian, 3rd – 6th October 1999.
New Treatments for Breast Carcinoma. The Hong Kong Society of Radiation Therapy and
Oncology, Hong Kong, 7th October 1999.
Advances in the Chemotherapy of Bladder Cancer. Eli Lilly Regional Medical Conference,
Singapore, March 4th – 5th 2000.
Role of PET scanning in Urological Tumours. Conjoint meeting of the Genito-Urinary
Oncology Group and the Urological Society of Australia. Sydney, 24th March 2000.
New Chemotherapeutic Agents for Bladder Cancer. Phillipine Urological Society, Manila,
June 9th 2000.
The treatment of non-small cell lung cancer in Australia. BMS Oncology Education
Weekend. Sydney, June 17th 2000.
Chemotherapy for Bladder Cancer. Eli Lilly Regional Medical Conference, Couran Cove,
October 27th – 28th 2000.
New chemotherapeutic agents for the management of advanced bladder cancer. Urological
Society of India Annual Scientific Meeting, Nagpur, India. January 19th 2001.
Systemic Therapy for Germ Cell Tumours. Best Practice Workshop in Urological Cancer.
Genito Urinary Oncology Group, Sydney June 22nd – 24th 2001.
The role of PET scanning in lung cancer management. New England Journal of Medicine
Symposium on Lung Cancer, at the Thoracic Society of Australia and New Zealand
Annual Scientific Meeting. Cairns 24th – 27th March 2002.
Cancer: Past Present and Future. Practical Points in Oncology Conference, Chiang Mai
University, Chaing Mai, Thailand. 10th July 2002.
Should we give 2nd or 3rd line chemotherapy for Non-Small Cell Lung Cancer. Medical
Oncology Group of Australia Annual Meeting. Barossa Valley 14th – 17th August 2002.
Current Chemotherapy for Stage IV Non Small Cell Lung Cancer. Medical Oncology
Group of Australia Annual Meeting. Barossa Valley 14th – 17th August 2002.
Lung Cancer Research Update. Astra Zeneca Weekend Oncology Workshop, Melbourne
7th – 8th September 2002
Chemo-radiotherapy for locally advanced non-small cell lung cancer: data and
18
controversies. Eli Lilly Regional Medical Conference Bangkok, Thailand. 22nd - 23rd
February 2003
Australian trials in lung cancer. 4th International Conference on Lung Cancer. Maui,
Hawaii, USA. 25th – 28th June 2003.
Will novel targeted therapies benefit lung cancer patients. Satellite Symposium, 10th
World Conference on Lung Cancer, Vancouver, Canada. 10th August 2003.
PET scanning for operable lung cancer. 10th World Conference on Lung Cancer,
Vancouver, Canada. 10th – 15th August 2003.
Communication in oncology. Grand Rounds, Royal Melbourne Hospital. 23rd October
2003.
Induction chemotherapy for stage 1 – 3 non-small cell lung cancer. 8th Asia Pacific Society
for Respirology meeting, Kuala Lumpur, Malaysia. 1st – 4th December 2003.
Current management of small cell lung cancer. 8th Asia Pacific Society for Respirology
meeting, Kuala Lumpur, Malaysia. 1st – 4th December 2003.
Update on EGFR inhibition in Cancer treatment. 9th Taiwan Joint Cancer Conference,
Astra Zeneca Satellite Symposium. Taipei, Taiwan. May 2nd 2004.
The promise of combination therapy of Alimta with Gemzar or other agents. Eli lilly
Global medical Conference, New Orleans, USA. 3rd – 4th June 2004.
Non-Small Cell Lung Cancer, Chemotherapy II. Invited discussant. ASCO annual
meeting, New Orleans, USA. June 5th - 8th 2004.
Pemetrexed for Mesothelioma. Eli Lilly Global Medical Conference, Orlando, USA. May
13th 2005.
Clinical Cancer Research in Australia. 18th APCC meeting, Seoul, South Korea September
7th – 9th 2005.
Multimodality Treatment of Cancer. Postgraduate Course in Oncology, Universiti Sains
Malaysia, Kota Bahru, Malaysia. September 29th – October 1st 2005
Chemotherapy for Small Cell and Non-Small Cell Lung Cancer. Postgraduate Course in
Oncology, Universiti Sains Malaysia, Kota Bahru, Malaysia. September 29th – October 1st
2005.
Integrating Chemotherapy and Novel Therapies in Cancer Management. Postgraduate
Course in Oncology, Universiti Sains Malaysia, Kota Bahru, Malaysia. September 29th –
October 1st 2005.
Future Multidisciplinary Lung Cancer Research. Australian Lung Cancer Conference,
Palm Cove , July 2nd 2006.
19
Innovations in the Treatment of Mesothelioma. First Asian Perspectives in Lung Cancer
Meeting. Shanghai, August 5th 2006.
Combined Modality Treatment Using Targeted Therapies. Chinese Society of Clinical
Oncology Annual Meeting, Beijing, September 16th 2006.
How Oncologists Use Clinical trial Results. Statistical Society of Australia “Challenges of
Running Oncology Clinical Trials Workshop”. Sydney October 27th 2006
Systemic Treatment for Mesothelioma. Education Session 12th World Conference on Lung
Cancer, Seoul, South Korea, 3rd September 2007
Lung Cancer. CanRevive (Chinese Community Cancer Support Service) Annual Meeting,
Sydney, October 12th 2007
Treatment of Mesothelioma. Lilly Oncology Weekend Symposium, Sydney, October 13th
2007
Controversies in the Management of Stage 3 Non-Small Cell Lung Cancer. Singapore
Society of Oncology, 2nd Annual Review Course, Singapore 25th January, 2008
New Therapeutic Approaches for Advanced non-Small Cell Lung Cancer. Singapore
Society of Oncology, 2nd Annual Review Course, Singapore 25th January, 2008
Systemic Treatment for Non-Melanoma Skin Cancer. Invited Speaker, Annual Scientific
meeting of the Clinical Oncological Society of Australia, Sydney, November 19th 2008
Epidermal Growth Factor Receptor Inhibitors. Invited speaker 13th World Conference on
Lung Cancer, to be held August 2009, San Francisco
20